Atezolizumab + Bevacizumab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-ATEZOLIZUMAB DRUG-BEVACIZUMAB |
|---|
| ID | REG-ATEZO-BEV |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-AASLD-HCC-2023 SRC-NCCN-HCC-2025 |
Notes
IMbrave150 — 1L unresectable HCC, Child-Pugh A only, ECOG ≤1. Mandatory pre-treatment EGD within 6 months; high-risk varices treated by ligation/banding before initiation. mOS 19.2 mo vs 13.4 sorafenib. AFP-secreting tumors derive larger benefit (subgroup analysis).
Used By
Indication
IND-HCC-SYSTEMIC-1L-ATEZO-BEV- IND-HCC-SYSTEMIC-1L-ATEZO-BEV